Back
75· Active
Health & Science2d 14h ago
The FDA has granted accelerated approval to donanemab, a monoclonal antibody treatment designed to slow the progression of early-stage Alzheimer's disease.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) and Eli Lilly
What
The FDA has granted accelerated approval to donanemab, a monoclonal antibody treatment designed to slow the progression of early-stage Alzheimer's disease.
When
Sat, 06 Jun 2026 19:10:06 GMT · 2d 14h ago
Where
Silver Spring, Maryland, USA · 39.0347°N, 76.9959°W
Why
Clinical trial data demonstrated a significant reduction in amyloid plaque buildup and a 35% slowing of cognitive decline in patients with high levels of protein markers.
The Frontline Impact
How this affects you
This provides a new therapeutic option for millions of families dealing with neurodegenerative conditions, though high costs and intense monitoring for side effects remain key hurdles for widespread use.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.